Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 299 participants.

Also called NCT01376557

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 299 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01376557
Other papers using this trial's data
  • Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy Diabetes care, 2015-03 DOI, PubMed 25216510, PMC5131876 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01376557. Randomized; quadruple masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2012-05 (actual). Results posted on 2014-10-31.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
75 mg LX4211
Intervention (Drug)
200 mg LX4211
Intervention (Drug)
400 mg LX4211
Intervention (Drug)
200 mg LX4211
Intervention (Drug)
Placebo
Lead sponsor
Lexicon Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01376557
Content hash
4bbd1acc10d8b284ea3945d98f2981b2dbdbf5f8a2d41add27ed8abf784be8d7